Standalone telementalhealth continues to be generously funded. Grow Therapy’s $150 million Series D brings their total funding to $328 million and their valuation to $3 billion. Their combination of in-person and telehealth visits with clinicians and psychiatrists is targeted to health plans, employers, and health systems. In-network plans include Humana, Cigna, UnitedHealthcare and Aetna. The fresh funding will be for expansion to the employer benefits market, within health systems for integration with primary care, and additional advanced AI tools. Grow claims that in 2025, they facilitated seven million visits, for a total since inception of 10 million therapy and medication management appointments. The round was led by TCV and Growth Equity at Goldman Sachs Alternatives, which had previously led Grow Therapy’s Series B and C respectively. Participating were new investors BCI and Menlo Ventures plus existing investors Sequoia Capital, SignalFire, and Transformation Capital. Grow joins well-funded competition Spring Health, with a valuation of $3.3 billion and Headway, with a $2.3 billion valuation. Blog/Release, Mobihealthnews, MedCity News, Reuters
UnityAI passes the Series A bar with $8.5 million. The round was led by Third Prime, with participation from Nashville Capital Network, Whistler Capital Partners, Max Ventures, Company Ventures, and other existing investors for a total funding of $15 million. Nashville-based UnityAI is a startup developing agentic AI to assist healthcare staff in scheduling for outpatient and specialty care practices. The agents assist with scheduling and rescheduling, confirmations, follow-ups, and referrals. It also integrates staffing operations – capacity optimization, shift management, PTO, and coverage–with the agents into what they call a “single continuously operating system”. The new funding will support continued efforts to scale go-to-market execution and extend its AI-powered operational capabilities. UnityAI integrates with major EHRs and is currently operating 300,000 patient interactions per month across hundreds of sites of care. UnityAI release, Mobihealthnews
And in local (to this Editor) news, Health Recovery Solutions buys Rimidi. Not the Italian Adriatic resort, Rimidi is an Atlanta-based software and services provider for chronic disease management and remote patient monitoring for diabetes and cardiometabolic conditions. Physician founded, it targeted to health systems, physician practices, value-based care organizations, and community health centers such as FQHCs and RHCs. No acquisition cost nor staff transition were disclosed. Dr. Lucienne Ide, MD, PhD Rimidi’s CEO and founder, joins HRS as chief medical officer.
Health Recovery Solutions (HRS) provides remote patient monitoring (RPM), chronic care management (CCM), and longitudinal virtual care. Headquartered in Hoboken, NJ across the Hudson from NYC, its last raise was $70 million in Series C funding back in 2021 via Edison Partners and LLR Partners. Several online sources report a revenue run rate between $23 and $50 million. Rimidi was relatively small, with its last funding in 2023 for $5 million, totaling $12.9 million from investors such as Eli Lilly and Village Capital. Notably, it was woman-led. The acquisition is expected to strengthen HRS’ EHR integrations and in managing diabetes and metabolic diseases within HRS’ PatientFirst Pathways care model. Release
Most Recent Comments